Enlitic Inc (ASX: ENL) - Share Price
- Current share price for ENL : $0.007
Enlitic Inc (ENL), an ASX-listed company, is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers.
ENL General Information +
| ASX Code | ENL |
| Website | N/A |
| Industry/Sector | Health Care Technology |
| Market Cap ($M) | 5 |
| ENL Share Price | $0.007 |
| Day High | $0.008 |
| Day Low | $0.007 |
| Last Close | $0.007 |
| ENL Share Price Movement | - ( No change ) |
Prices as at 16:40, 17 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Enlitic Inc (ENL) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Enlitic Inc (ENL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Enlitic Inc (ENL) price-sensitive announcements
ENL - Investor Presentation - Capital Raising and CN Conversion
Enlitic Inc.'s investor presentation focused on capital raising and the conversion of conv
Enlitic Inc (ENL)
3 Jul 2026 | 9:37 AM
3 Jul 2026 | 9:37 AM
ENL - A$15m Conditional Placement and Proposed Note Conversion
Enlitic Inc. has announced a conditional placement to raise A$15 million through the issua
Enlitic Inc (ENL)
3 Jul 2026 | 9:37 AM
3 Jul 2026 | 9:37 AM
ENL - First Australian Ensight Contract Secured with Lumus Imaging
On July 1, 2026, Enlitic Inc. announced its first Australian Ensight subscription agreemen
Enlitic Inc (ENL)
1 Jul 2026 | 9:10 AM
1 Jul 2026 | 9:10 AM
ENL - Trading Halt
The document is a market announcement regarding a trading halt for Enlitic Inc. (ASX: ENL)
Enlitic Inc (ENL)
1 Jul 2026 | 8:39 AM
1 Jul 2026 | 8:39 AM
Enlitic Inc (ENL) Recent ASX Announcements
ENL Financial Summary
| Year to Dec | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$19.98 | -$2.70 | -78.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$24.51 | -$12.90 | -97.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$22.74 | -$474.90 | 0.00% | 0.00 | 0.00 | 0.00% | 0.0% |
ENL Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| 4DMedical Limited (4DX) | $2,273M | 0.3304 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Enlitic Inc (ENL) | $6M | -0.7883 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Pro Medicus Limited (PME) | $20,247M | 0.3919 | 0.2545 | 0.2962 | 176.0309 | 140.3200 | 108.2556 | 0.28% | 0.36% | 0.47% |
ENL Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Michael Karl-Gerhard Sistenich | Chief Executive Officer, Executive Director | 1 Nov 2018 |
| Mr Lawrence Bernard Gozlan | Non-Executive Chairman, Non-Executive Director | 23 Sep 2019 |
| Mr Sergio Duchini | Non-Executive Director | 13 Dec 2023 |
| Ms Lisa Pettigrew | Non-Executive Director | 4 Mar 2024 |
Enlitic Inc (ENL) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 10 Feb 2026 | SISTENICH, Michael | Issued | Convertibles | 100,000 | $1.000 | $100,000.000 |
| 10 Feb 2026 | DUCHINI, Sergio | Issued | Convertibles | 25,000 | $1.000 | $25,000.000 |
| 13 Jun 2025 | SISTENICH, Michael | Issued | Indirect Shares | 1,250,000 | $0.040 | $50,000.000 |
See all changes in directors' interest & trades for Enlitic Inc (ENL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
ENL Management
| Name | Position |
|---|---|
| Darren Stuart Scotti | Chief Financial Officer,Company Secretary |
| Steve Rankin | Chief Strategy Officer |
| Dan Kozimor | Chief Technology Officer |
ENL Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Enlitic Inc (ENL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 161,999,982 (19.44%) | J P Morgan Nominees Australia Pty Limited |
| 115,893,602 (13.91%) | Citicorp Nominees Pty Limited |
| 26,250,000 (3.15%) | Jagen Pty Ltd |
ENL Calendar of Events
| Date | Event |
|---|---|
| 26 February 2027 | Report (Annual) |
| 26 February 2027 | Report (Prelim) |
| 26 August 2026 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
